XML 65 R36.htm IDEA: XBRL DOCUMENT
v2.4.1.9

SELECTED QUARTERLY INFORMATION - UNAUDITED (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2014
Selected Quarterly Financial Information [Abstract] |
Selected Quarterly Information |
| First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter
| (In thousands, except per share data)
Total revenue, net: |  |  |  |  |  |  |
2014 | $ | 215,059 |  |  | $ | 231,351 |  |  | $ | 229,719 |  |  | $ | 252,176 |
2013 (As adjusted)* | 196,652 |  |  | 205,547 |  |  | 213,246 |  |  | 220,769 |
Gross margin: |  |  |  |  |  |  |
2014 | $ | 132,676 |  |  | $ | 144,375 |  |  | $ | 143,745 |  |  | $ | 154,708 |
2013 (As adjusted)* | 117,040 |  |  | 123,718 |  |  | 131,479 |  |  | 136,932 |
Net income (loss): |  |  |  |  |  |  |
2014 | $ | 2,206 |  |  | $ | 4,825 |  |  | $ | 9,807 |  |  | $ | 17,166 |
2013 (As adjusted)* (1) | (6,028 | ) |  | 1,520 |  |  | (30,330 | ) |  | 13,771 |
Basic net income (loss) per common share (2): |  |  |  |  |  |  |
2014 | $ | 0.07 |  |  | $ | 0.15 |  |  | $ | 0.30 |  |  | $ | 0.53 |
2013 (As adjusted)* | (0.22 | ) |  | 0.05 |  |  | (1.09 | ) |  | 0.46 |
Diluted net income (loss) per common share (2): |  |  |  |  |  |  |
2014 | $ | 0.07 |  |  | $ | 0.15 |  |  | $ | 0.30 |  |  | $ | 0.52 |
2013 (As adjusted)* | (0.22 | ) |  | 0.05 |  |  | (1.09 | ) |  | 0.45 |
*See Note 2 of these consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax. (1) The first quarter of 2013 was negatively impacted by a voluntary recall of certain products manufactured in the Company's Añasco, Puerto Rico facility. On July 31, 2013, the Company performed the annual goodwill impairment test which resulted in a non-cash goodwill impairment charge of $46.7 million for its U.S. Spine reporting unit, which is a part of the U.S. Spine and Other reportable segment. The Company incurred incremental costs related to the implementation of its global enterprise resource planning system in the first, second, third, and fourth quarters of 2013 of $6.1 million, $7.6 million, $5.0 million and $5.6 million, respectively. The Company incurred costs related to the remediation of the FDA warning letters at its manufacturing facilities of $2.1 million, $3.0 million, $2.8 million and $0.4 million in the first, second, third and fourth quarters of 2013, respectively. (2) Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not necessarily add to the annual amount because of differences in the weighted average common shares outstanding during each period principally due to the effect of the Company’s issuing shares of its common stock during the year.

X
- Definition Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=35737889&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SelectedQuarterlyFinancialInformationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration